The stock is likely to react positively to the strong efficacy and safety data, with the next major catalyst being the completion of the randomized Phase 2 trial enrollment in 2026. Traders should monitor for updates on the 20 mg/kg cohort's median duration of response and overall survival, as well as progress on the Roche and Sanofi collaborations, which could provide non-dilutive funding and validate the platform's potential.
Price Chart
Executive Summary
Adagene's 20-F filing, combined with recent 6-Ks, confirms strong clinical progress for its lead candidate muzastotug, showing a 29% confirmed ORR in MSS CRC patients and a favorable safety profile with no Grade 4/5 TRAEs. The company has a cash runway into early 2028, bolstered by its ATM offering. This positive data, coupled with upcoming catalysts like a randomized Phase 2 trial and collaborations with Roche and Sanofi, positions the company for significant near-term value inflection.
Key Facts
- Lead candidate muzastotug showed a 29% confirmed overall response rate (ORR) in 21 MSS CRC patients at the 20 mg/kg dose cohort.
- Median overall survival (OS) was 19.4 months for the 10 mg/kg cohort, with a favorable safety profile (4% discontinuation rate, no Grade 4/5 TRAEs).
- Cash and cash equivalents were $74.5 million as of December 31, 2025, with a cash runway extending into early 2028.
- The company is on track to complete enrollment of a randomized Phase 2 dose-optimization study in 2026, a key regulatory milestone.
- Significant collaborations are in place with Roche (triplet combination trial in HCC) and Sanofi (up to $840M in potential milestones).
Financial Impact
The positive clinical data and extended cash runway significantly de-risk the company's lead program. The 29% ORR is a strong signal of efficacy in a hard-to-treat population, and the clean safety profile supports higher dosing, which could lead to a best-in-class profile. This improves the probability of successful Phase 3 trials and eventual commercialization.
Risk Factors
- The company has a history of net losses and will require additional funding beyond 2028, which could lead to future dilution.
- As a Cayman Islands company with operations in China, it faces regulatory risks related to PCAOB inspections and potential delisting if U.S.-China tensions escalate.
- The biotech sector is highly competitive, and other CTLA-4 inhibitors or novel immunotherapies could emerge as superior treatments.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 11 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 20-F Filing (ADAG) — Batch item 1 | 0001104659-26-038612 |
| Document: adag-20251231xex12d1.htm | 0001104659-26-038618 |
| Document: adag-20251231xex15d2.htm | 0001104659-26-038612 |
| Document: adag-20251231xex12d2.htm | 0001104659-26-038612 |
| Document: adag-20251231xex15d1.htm | 0001104659-26-038612 |
| Document: adag-20251231xex13d2.htm | 0001104659-26-038612 |
| Document: adag-20251231xex13d1.htm | 0001104659-26-038612 |
| Document: adag-20251231xex15d3.htm | 0001104659-26-038612 |
| Document: 0001104659-26-038612-index-headers.html | 0001104659-26-038612 |
| Document: 0001104659-26-038612-index.html | 0001104659-26-038612 |
| Document: 0001104659-26-038612.txt | 0001104659-26-038612 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 25, 2026 4w ago | 6-K | $3.20 | awaiting T+60 | — | $2.49 (−22.19%) |
Sep 22, 2026 4w ago | 6-K | $3.23 | awaiting T+60 | — | $2.49 (−22.91%) |
Sep 10, 2026 6w ago | 6-K | $3.31 | awaiting T+60 | — | $2.49 (−24.77%) |
Sep 9, 2026 6w ago | 6-K | $3.27 | awaiting T+60 | — | $2.49 (−23.85%) |
Aug 16, 2026 10w ago | Institutional Cluster | $3.83 | awaiting T+60 | — | $2.49 (−34.99%) |
Aug 12, 2026 10w ago | 6-K | $3.75 | awaiting T+60 | — | $2.49 (−33.60%) |
Aug 12, 2026 10w ago | Press Release | $3.75 | awaiting T+60 | — | $2.49 (−33.60%) |
Jul 6, 2026 16w ago | 6-K | $3.93 $3.21 | ▼ −18.32% | ▼ −20.04% | $2.49 (−36.64%) |
Apr 17, 2026 27w ago | 6-K | $3.89 $3.67 | ▼ −5.66% | ▼ −12.43% | $2.49 (−35.99%) |
Apr 2, 2026 29w ago | 6-K | $3.99 $4.20 | ▼ −5.26% | ▲ +8.90% | $2.49 (+37.59%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers